Andrew Powaleny Andrew Powaleny is Director of Public Affairs at PhRMA. Before joining PhRMA in 2015, he worked at the House Energy and Commerce Committee and later as a communications consultant. Andrew came to Washington, D.C. via Connecticut and proudly sings with the Gay Men’s Chorus of Washington, runs with the DC Front Runners and serves on the Alumni Council for The Fund for American Studies. He is also a member of the National Lesbian Gay Journalists Association.
Recent Posts
ICYMI: 2019 brings innovative medicines to patients
By Andrew Powaleny | January 17, 2020
New reports from the U.S. Food and Drug Administration (FDA) show a total of 56 novel new medicines were approved in 2019. Among these, 48 were approved by the Center for Drug Evaluation and...
Read More
ICYMI: Cancer death rate declines at record levels thanks to innovative medicines
By Andrew Powaleny | January 9, 2020
Each year, the American Cancer Society estimates the number of new cancer cases and deaths that will occur in the United States. For nearly 30 years, the trend towards fewer cancer deaths has been...
Read More
R&D Focus: Four ways the biopharmaceutical industry leads in delivering new treatments and cures
By Andrew Powaleny | December 9, 2019
In recent years, rapid advances in scientific discovery have ushered in a new era of medicine, transforming our ability to treat, and in some cases cure, some of the most challenging diseases,...
Read More
Event tomorrow: Maintaining America’s leadership in access and innovation
By Andrew Powaleny | October 16, 2019
Each year, biopharmaceutical companies invest nearly $100 billion in the discovery of new treatments and cures. Despite a challenging research and development (R&D) process, consistently high...
Read More
Nearly 140 medicines in development to treat mental illness
By Andrew Powaleny | October 10, 2019
Today is World Mental Health Day, a moment where we reflect about the challenges we still face towards better treatment of mental illness and its impact on patients.
Read More
IP Explained: Understanding biopharmaceutical innovation
By Andrew Powaleny | July 30, 2019
Over the past 25 years, prescription medicines have transformed the trajectory of many debilitating diseases and conditions, including heart disease, HIV/AIDS, cancer and hepatitis C, resulting in...
Read More
Event tomorrow: Improving access and affordability for America’s seniors
By Andrew Powaleny | May 7, 2019
Medicare Parts B and D have played an important role in providing seniors with access to the lifesaving treatments they need and have been successful in delivering value to both the health care...
Read More
New report shows more than 160 medicines in development for diabetes and related conditions
By Andrew Powaleny | April 24, 2019
Diabetes represents a significant public health issue in the U.S. It affects more than 30 million Americans, including around 7.2 million who are undiagnosed. Additionally, there are close to 1.5...
Read More
New report shows nearly 20 innovative medicines in development for sickle cell disease
By Andrew Powaleny | April 2, 2019
Sickle cell disease (SCD) is the most common inherited blood disorder in the United States, afflicting nearly 100,000 Americans. Patients with SCD have sickle-shaped red blood cells, which have...
Read More
130 medicines in development for asthma, allergies and other respiratory diseases
By Andrew Powaleny | February 21, 2019
Millions of Americans suffer from respiratory diseases, including Asthma and chronic obstructive pulmonary disease (COPD). Together, these two diseases affect the day-to-day lives of over 40...
Read More
Medicare Monday (100)
340B Spotlight (43)
Cost & Consequence (0)
